Previous 10 | Next 10 |
SAN DIEGO, Oct. 30, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that it will report third quarter 2019 financial results after the close...
– 56% confirmed ORR in 18 efficacy-evaluable HNSCC patients with HRAS mutant variant allele frequency ≥ 20% – – Median progression-free survival of 6.1 months vs. 2.8 months on last prior therapy – – 8 efficacy-evaluable patients enrolled since...
– Data from Phase 2 clinical trial of tipifarnib in HRAS mutant HNSCC selected for short-talk during Spotlight on Proffered Papers session on Tuesday, October 29 th – – Previously announced poster presentation rescheduled to take place following oral presentation ...
Noteworthy events during the week of October 20 - 26 for healthcare investors. More news on: Foamix Pharmaceuticals Ltd., Axovant Gene Therapies Ltd., GlaxoSmithKline plc, Healthcare stocks news, , Read more ...
SAN DIEGO, Oct. 16, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that an abstract related to the Company’s Phase 2 clinical trial ...
SAN DIEGO, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced the appointment of veteran commercial executive Diane Parks to its board...
– KO-539 is a first-in-class small molecule inhibitor of the menin-MLL interaction – – First-in-human trial to determine MTD, expand to genetic subgroups such as NPM1 – SAN DIEGO, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clini...
Results from an investigator-sponsored Phase 2 clinical trial evaluating Kura Oncology's ( KURA +1.9% ) tipifarnib in patients with relapsed/refractory HRAS mutation-positive urothelial carcinoma showed a positive effect on progression-free survival (PFS) at month 6. More news on: Kur...
– Confirmed objective responses achieved in five of 13 evaluable patients – – Primary endpoint met prior to completion of enrollment with four patients experiencing progression-free survival greater than 6 months – – Proof-of-concept trial sponsored by...
The following slide deck was published by Kura Oncology, Inc. in conjunction with this Read more ...
News, Short Squeeze, Breakout and More Instantly...
2024-06-25 22:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-25 08:15:04 ET H.C. Wainwright analyst issues BUY recommendation for KURA on June 25, 2024 06:44AM ET. The previous analyst recommendation was Buy. KURA was trading at $21.08 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current...
– Ziftomenib induces insulin production, improves insulin sensitivity and reduces insulin resistance in preclinical model of type 2 diabetes – – Kura advancing multiple, next-generation menin inhibitor drug candidates targeting diabetes and other metabolic diseases ...